Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Evista Breast Cancer Market May Build On Osteo Acceptance

Executive Summary

Physician experience in treating osteoporosis patients with Lilly's Evista (raloxifene) might improve the product's uptake for reducing the risk of breast cancer

You may also be interested in...



Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer

Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial

Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer

Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial

Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning

FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling

Related Content

UsernamePublicRestriction

Register

PS048453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel